|Photothermal therapy combined with cell-based drug-loading technology has made new progress in anti-tumor field|
|Submission:张灿课题组 Date:2019-01-01 Page View:39|
In recent years, our research group has made great achievements in the field of cell-based drug delivery research, including Nat Nanotechnol, 2017, 12(7):692-700, and has successfully established a cell-based drug-loading platform. Recently, we published the latest research results of cell-carrier technology in Advanced Materials (IF 21.950), "Transforming Weakness into Strength: Photothermal-Therapy-Induced Inflammation Enhanced Cytopharmaceutical Chemotherapy as a Combination Anticancer Treatment". Zhang Lei and Zhang Ying are the co-first authors of this article. Professor Zhang Can and Associate Professor Su Zhigui are co-corresponding authors.
In this work, we combined photothermal therapy (PTT) with a neutrophil-based chemotherapy drug delivery system. We found inflammatory cells were recruited in the inflammation sites caused by photothermal therapy after killing tumor cells. We exploited the mouse neutrophils to load the chemotherapy drug paclitaxel, then paclitaxel-loaded neutrophils were re-injected into the mice. After PTT treatment, an inflammatory reaction occured at the tumor sites, and neutrophils carrying paclitaxel were recruited to tumor sites, achieving inflammation-mediated active targeting (IMAT), which enhanced antitumor efficacy and reduced overall toxic side effects.
This work combines PTT and IMAT organically, enriching and expanding the application of high-efficiency drug delivery technology based on cells for clinical treatment.